Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed N.V. - Common Stock (NQ: AFMD )

1.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 433,961
Open 1.090
Bid (Size) 1.050 (13)
Ask (Size) 1.080 (9)
Prev. Close 1.080
Today's Range 1.030 - 1.140
52wk Range 1.030 - 8.950
Shares Outstanding 15,227,463
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
From Affimed N.V.
Via GlobeNewswire

Performance

YTD
-20.00%
-20.00%
1 Month
-28.48%
-28.48%
3 Month
-67.37%
-67.37%
6 Month
-80.15%
-80.15%
1 Year
-81.69%
-81.69%

More News

Read More
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
A Look Ahead: Affimed's Earnings Forecast
Via Benzinga
Why Affimed Shares Are Soaring
Via Benzinga
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Third Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the Cantor Global Healthcare Conference 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Second Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed Appoints Shawn M. Leland as Chief Executive Officer
From Affimed N.V.
Via GlobeNewswire
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
From Affimed N.V.
Via GlobeNewswire
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Affimed Reports First Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
From Affimed N.V.
Via GlobeNewswire
Why Is German Biotech Affimed Stock Soaring On Monday?
Via Benzinga
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
From Affimed N.V.
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
From Affimed N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.